Revolution Medicines Targets Pancreatic Cancer Breakthrough with Experimental RAS Inhibitor
, , ,

Revolution Medicines Targets Pancreatic Cancer Breakthrough with Experimental RAS Inhibitor

Revolution Medicines is approaching a pivotal moment in oncology as it prepares to unveil Phase 3 clinical trial data for its experimental drug, daraxonrasib. Designed as a daily oral medication, the drug specifically targets RAS mutations, which are implicated in roughly 90% of pancreatic cancer cases. Because pancreatic cancer remains one of the most lethal […]
Eli Lilly Launches Foundayo: A New Oral Frontier in Weight Management
, , , , ,

Eli Lilly Launches Foundayo: A New Oral Frontier in Weight Management

The U.S. Food and Drug Administration has officially approved Eli Lilly’s Foundayo, a once-daily oral GLP-1 treatment that represents a major shift in the weight management landscape. By offering a pill-based alternative to traditional injectable therapies, the company aims to increase accessibility for patients who may be hesitant about needles or require more flexible dosing […]
Eli Lilly Challenges Legislative Push for ‘Most Favored Nation’ Drug Pricing
, , , , ,

Eli Lilly Challenges Legislative Push for ‘Most Favored Nation’ Drug Pricing

Pharmaceutical leader Eli Lilly is mounting a significant opposition campaign against current efforts by the White House to codify ‘most favored nation’ (MFN) drug pricing mandates into federal law. CEO Dave Ricks has publicly criticized the proposed legislation, arguing that transitioning from voluntary agreements to a rigid statutory framework could have detrimental effects on the […]